NEW YORK, Dec. 20 – German pharmaceutical company Schering said Thursday it had agreed to make a 10 percent equity investment in MorphoSys of Martinsreid, Germany, and to work together with the biotechnology firm to develop antibody therapeutics and diagnostics. 

Under the terms of the three-year deal, the companies said they would work together exclusively to develop at least five therapeutic and several in-vivo diagnostics antibody projects.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.